Supernus Announces Second Quarter 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Supernus Pharma (SUPN) Reports Q2 EPS of 8c, Guides to Cash Flow Positive in 2015
August 11, 2014 5:10 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.08, may not compare to the analyst estimate of ($0.16). Revenue for the quarter came in at $29.67 million versus the consensus estimate of $19.85 million.
Financial Guidance
With the recognition of royalty revenues of $30 million in July, the Company is... More
